Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.

ABSTRACT: In the HELIOS-B randomized clinical trial, the RNA interference therapeutic agent vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events among patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). In this secondary analysis of HELIOS-B, we evaluated vutrisiran's effects on echocardiographic measures of cardiac structure and function in patients with ATTR-CM receiving vutrisiran or placebo (n = 654, 93% men). At 30 months after treatment, as compared to the placebo group, vutrisiran treatment attenuated increases in mean left ventricular (LV) wall thickness (least squares mean difference: -0.4 mm; 95% confidence interval (CI): -0.8, 0.0; P = 0.03) and LV mass index (-10.6 g m^-2; 95% CI: -18.0, -3.3; P < 0.01). Vutrisiran

SUBMITTER: Jering KS 

PROVIDER: S-EPMC12532587 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature